Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant mutants of rhabdovirus and methods of use thereof

A rhabdovirus and cytopathic technology, applied in the direction of viruses, vectors, metabolic diseases, etc., can solve the problems that wild-type tropism is not easy to overcome

Inactive Publication Date: 2006-08-16
UNIV OF TENNESSEE RES FOUND
View PDF12 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The widespread use of viral gene therapy vectors is limited by the fact that the natural wild-type tropism of the utilized viral vectors is often not easily overcome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant mutants of rhabdovirus and methods of use thereof
  • Recombinant mutants of rhabdovirus and methods of use thereof
  • Recombinant mutants of rhabdovirus and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0216] Example 1: Mutations in the M protein of VSV produce infectious, non-cytopathic viruses

[0217] Materials and methods

[0218] Site-directed mutagenesis of VSV expressing the GFP gene was performed. BHK-21 cells were then infected with the mutated VSV. Virus particles were concentrated and viral RNA was isolated from cell culture supernatants by ultracentrifugation. Full-length cDNAs of NCP-12 variants were obtained using reverse transcription-PCR. The M gene and cDNA were subjected to automated sequence analysis.

[0219] Cultured infected BHK-21 (MOI 10) cells and cell infectivity and morphology were determined by fluorescence microscopy at the indicated times. Round cells were aspirated from the culture and the culture was washed several times with gentle aspiration, then incubated and checked periodically. After 7 days, GFP-positive cells were detected in the culture, indicating infection, and the culture supernatant was harvested and aliqu...

Embodiment 2

[0228] Example 2: Mutations in the M protein of VSV do not affect cell tropism

[0229] Materials and methods:

[0230] The following cell types were treated with rVSV / M at a multiplicity of infection of 10 NCP12.1 Infection: BHK, CV-1, Vero or HeLa cells. Cells were incubated at 37°C for 12 or 24 hours, fixed in 3% paraformaldehyde and washed twice with phosphate buffered saline (PBS) containing 50 mM glycine. Cells were then examined for GFP expression by fluorescence microscopy (Zeiss Axiophot, West Germany) and morphology was assessed by phase contrast microscopy.

[0231] result

[0232] To determine non-cytopathic rVSV / M NCP12.1Whether cell tropism was altered, BHK, CV-1, Vero and HeLa cells were infected at a multiplicity of infection of 10 (FIG. 7), and infection was determined as a function of GFP expression. Regardless of cell type, rVSV / M NCP12.1 Both were able to infect and replicate intracellularly without any si...

Embodiment 3

[0233] Example 3: Development of Advanced Vectors for Gene Therapy Applications

[0234] Materials and methods

[0235] Recombinant VSV M mutants were generated as described above. Mutated viruses were grown and recovered during infection of BHK-21 cells by co-expression with plasmids expressing N, P and L proteins. The mutated virus expresses M NCP12.1 proliferate in cells. Supernatants from cells infected with rVSV-ΔM (VSV replicon) were pre-treated with 5 μg of pc-M 24 h before NCP12.1 Plasmid-transfected cells. Cells were fixed 24 hours after infection and probed with an N-specific monoclonal antibody labeled with a rhodamine-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc.).

[0236] result

[0237] Previous attempts to recover mutated or missing M protein VSV ([Delta]M-VSV) failed, presumably because the toxic effect of the M protein kills the cells thereby limiting the amount of M ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The present invention relates to recombinant Rhabdoviridae, isolated nucleic acids, vectors, cells and compositions comprising same. The recombinant Rhabdoviridae, isolated nucleic acids, vectors, cells and compositions express Rhabdoviral proteins including a mutated matrix protein (M) and / or a mutated glycoprotein (G), in addition to expression of at least one foreign nucleic acid. The present invention also relates to methods of use thereof, including their use in vivo, in anti-cancer applications, such as in the treatment of gliomas. The recombinant Rhabdoviridae of the present invention are also useful in gene therapy and vaccine applications.

Description

field of invention [0001] The present invention relates to recombinant bombs expressing rhabdovirus proteins comprising a mutated matrix protein (M) and / or a mutated glycoprotein (G) in addition to at least one exogenous nucleic acid contained within its genome. Symviridae virus. The present invention also relates to its application method, including its application in vivo, anti-cancer application such as treatment of glioma. The recombinant Rhabdoviridae of the invention are also useful in gene therapy and vaccine applications. Background of the invention [0002] Despite tremendous progress in the development of suitable vectors for gene delivery in therapeutic applications, many obstacles remain, especially in the development of efficient delivery systems for gene therapy and in the development of vaccines and their impact on anticancer treatments obstacle. [0003] Viral vectors for gene therapy typically do not lyse the cells they target. Viral vectors for gene the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12P21/06C12N15/00C12N15/63C12N15/86A01N63/00A61K45/00C12N15/09A61K31/7088A61K35/76A61K35/766A61K39/00A61K39/07A61K48/00A61P1/16A61P3/10A61P5/14A61P9/00A61P9/12A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P19/02A61P19/10A61P21/04A61P25/00A61P25/14A61P25/16A61P25/18A61P25/24A61P25/28A61P27/02A61P27/16A61P29/00A61P31/04A61P35/00A61P37/04A61P37/06C07K14/145C12N7/00C12N7/04C12Q1/02C12Q1/68G01N33/50G01N33/574
CPCC12N2760/20232A61K39/07C07K2319/00C12N2760/20222A61K2039/5256C12N2760/20122A61K38/21C12N7/00A61K38/1709C07K14/005C12N2760/20151A61K2039/55538A61K38/208C12N2760/20143A61K2039/5254G01N33/5011C12N2840/20C12N2810/60A61K48/00C12N2760/20261A61K39/00A61K35/766A61K38/2013C12N15/86A61P1/16A61P11/00A61P11/06A61P13/12A61P17/00A61P17/02A61P17/06A61P19/02A61P19/10A61P21/04A61P25/00A61P25/14A61P25/16A61P25/18A61P25/24A61P25/28A61P27/02A61P27/16A61P29/00A61P31/04A61P35/00A61P37/04A61P37/06A61P5/14A61P9/00A61P9/12A61P3/10A61K2300/00
Inventor 迈克尔·A.·惠特克林顿·S.·罗比森希曼吉·R.·贾亚卡马克·A.·米勒
Owner UNIV OF TENNESSEE RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com